CN107281202A - 一种复方硫酸卡那霉素注射液及其制备方法 - Google Patents
一种复方硫酸卡那霉素注射液及其制备方法 Download PDFInfo
- Publication number
- CN107281202A CN107281202A CN201710528444.6A CN201710528444A CN107281202A CN 107281202 A CN107281202 A CN 107281202A CN 201710528444 A CN201710528444 A CN 201710528444A CN 107281202 A CN107281202 A CN 107281202A
- Authority
- CN
- China
- Prior art keywords
- kanamycin sulfate
- injection liquid
- compound
- solution
- sulfate injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960002064 kanamycin sulfate Drugs 0.000 title claims abstract description 47
- 238000002347 injection Methods 0.000 title claims abstract description 33
- 239000007924 injection Substances 0.000 title claims abstract description 33
- 239000007788 liquid Substances 0.000 title claims abstract description 30
- -1 compound kanamycin sulfate Chemical class 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 26
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 claims abstract description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229960000583 acetic acid Drugs 0.000 claims abstract description 13
- 239000012362 glacial acetic acid Substances 0.000 claims abstract description 13
- 239000008215 water for injection Substances 0.000 claims abstract description 13
- 229960000469 flunixin meglumine Drugs 0.000 claims abstract description 12
- MGCCHNLNRBULBU-WZTVWXICSA-N flunixin meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O MGCCHNLNRBULBU-WZTVWXICSA-N 0.000 claims abstract description 12
- 239000003182 parenteral nutrition solution Substances 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 239000000243 solution Substances 0.000 claims description 30
- 238000003756 stirring Methods 0.000 claims description 10
- 241000282898 Sus scrofa Species 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 241000894006 Bacteria Species 0.000 abstract description 5
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 4
- 238000001228 spectrum Methods 0.000 abstract description 3
- 230000000843 anti-fungal effect Effects 0.000 abstract description 2
- 229940121375 antifungal agent Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 229960000588 flunixin Drugs 0.000 description 6
- NOOCSNJCXJYGPE-UHFFFAOYSA-N flunixin Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O NOOCSNJCXJYGPE-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- ZWMNTFJERFRROC-UHFFFAOYSA-N 2-benzyl-3-methoxypyridine Chemical compound COC1=CC=CN=C1CC1=CC=CC=C1 ZWMNTFJERFRROC-UHFFFAOYSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000187708 Micromonospora Species 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 208000030303 breathing problems Diseases 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000027096 gram-negative bacterial infections Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了一种复方硫酸卡那霉素注射液，属于兽药制剂技术领域。该复方硫酸卡那霉素注射液种每1000L注射液是由以下原料制成的：氟尼辛葡甲胺30‑110kg、硫酸卡那霉素30‑110kg、甲氧苄啶50‑80kg、依地酸二钠1‑20kg、95％乙醇100‑400L、冰醋酸1‑10L，其余为注射用水。本发明的复方硫酸卡那霉素注射液抗菌谱广，扩大抗菌范围，能综合治疗猪副伤寒病及一些并发症，疗效高且快，减少细菌的耐药几率，增加疗效。
Description
技术领域
本发明涉及兽药领域，尤其是一种复方硫酸卡那霉素注射液及其制备方法。
背景技术
近年来，随着畜牧业的规模化、集约化发展，养殖密度的增加，多种疾病尤其是畜禽呼吸系统类疾病日渐增多，而临床上频繁使用抗菌药，病菌极易产生耐药性，这都大大增加的畜禽的养殖成本，探索一种长效的治疗呼吸道疾病药物是解决畜牧业生产中减少药物残留、降低饲养成本、提高经济效益的重要途径之一。
猪副伤寒病是猪常见的一种传染病，对养猪业威胁很大，常为冬季仔猪腹泻的防治重点，若不能确诊进行治疗或因诊断失误，往往给养猪业带来极大损失。近年来常将硫酸卡那霉素作为治疗或预防猪副伤寒病的首选药，硫酸卡那霉素由小单孢菌所产生，为一种多组分抗生素，对大肠杆菌、克雷伯氏菌、变形杆菌、巴氏杆菌、沙门氏菌、绿脓杆菌等革兰氏阴性菌有抗菌作用。主要用于革兰氏阴性细菌感染的抗菌素。目前的硫酸卡那霉素用于治疗猪副伤寒的效果不太理想，市场急需一种针对猪副伤寒治疗效果好，既能增强猪抵抗力，又能治疗多种病菌、病毒引起的混合感染及危重病症。
发明内容
本发明的目的在于克服现有技术的不足之处，提供一种抗菌谱广、疗效高且快、用药次数少的复方硫酸卡那霉素注射液及其制备方法。
本发明采用以下技术方案：
一种复方硫酸卡那霉素注射液，每1000L注射液是由以下原料制成的：氟尼辛葡甲胺30-110kg、硫酸卡那霉素30-110kg、甲氧苄啶50-80kg、依地酸二钠1-20kg、95％乙醇100-400L、冰醋酸1-10L，其余为注射用水。
所述的复方硫酸卡那霉素注射液，每1000L注射液是由以下原料制成的：氟尼辛葡甲胺80kg、硫酸卡那霉素70kg、甲氧苄啶65kg、依地酸二钠10kg、95％乙醇300L、冰醋酸8L，其余为注射用水。
一种上述的复方硫酸卡那霉素注射液的制备方法，它包括以下步骤：
(1)将甲氧苄啶溶解于冰醋酸中，得到溶液1；
(2)将依地酸二钠放入95％乙醇中，搅拌10-25分钟至澄清得溶液2；
(3)取注射用水300L，依次加入硫酸卡那霉素、氟尼辛葡甲胺搅拌溶解得溶液3；
(4)将上述制得的溶液1，溶液2，溶液3混合，再加注射用水至1000L，搅拌均匀，保持15-20分钟，待药液澄明后即得复方硫酸卡那霉素注射液。
本发明的优点和积极效果是：
1、本发明采用硫酸卡那霉素与氟尼辛葡甲胺的复方制剂，再加上抗菌增效剂甲氧苄啶，抗氧剂依地酸二钠，四药联合使用，对革兰氏阴性菌、阳性菌都有抗菌作用，抗菌谱广，扩大抗菌范围，能综合治疗猪副伤寒病及一些并发症，疗效高且快，减少细菌的耐药几率，增加疗效。
2、本发明能有效缓解患畜身体的应激反应，实验证明，硫酸卡那霉素与氟尼辛葡甲胺联合使用可使疗效增强，可在多种畜种上应用，尤其是用于猪副伤寒的治疗，不仅能减少用药次数，还能提高其的治愈率，使猪增加体重更快。
具体实施方式
下面结合具体实施例对本发明做进一步的详细说明。
实施例1
一种复方硫酸卡那霉素注射液，每1000L注射液是由以下原料制成的：氟尼辛葡甲胺30-110kg、硫酸卡那霉素30-110kg、甲氧苄啶50-80kg、依地酸二钠1-20kg、95％乙醇100-400L、冰醋酸1-10L，其余为注射用水。
一种上述的复方硫酸卡那霉素注射液的制备方法，它包括以下步骤：
(1)将甲氧苄啶溶解于冰醋酸中，得到溶液1；
(2)将依地酸二钠放入95％乙醇中，搅拌10-25分钟至澄清得溶液2；
(3)取注射用水300L，依次加入硫酸卡那霉素、氟尼辛葡甲胺搅拌溶解得溶液3；
(4)将上述制得的溶液1，溶液2，溶液3混合，再加注射用水至1000L，搅拌均匀，保持15-20分钟，待药液澄明后即得复方硫酸卡那霉素注射液。
实施例2
一种复方硫酸卡那霉素注射液，每1000L注射液是由以下原料制成的：氟尼辛葡甲胺30-110kg、硫酸卡那霉素30-110kg、甲氧苄啶50-80kg、依地酸二钠1-20kg、95％乙醇100-400L、冰醋酸1-10L，其余为注射用水。
一种上述的复方硫酸卡那霉素注射液的制备方法，它包括以下步骤：
(1)将甲氧苄啶溶解于冰醋酸中，得到溶液1；
(2)将依地酸二钠放入95％乙醇中，搅拌10-25分钟至澄清得溶液2；
(3)取注射用水300L，依次加入硫酸卡那霉素、氟尼辛葡甲胺搅拌溶解得溶液3；
(4)将上述制得的溶液1，溶液2，溶液3混合，再加注射用水至1000L，搅拌均匀，保持15-20分钟，待药液澄明后即得复方硫酸卡那霉素注射液。
实施例3
一种复方硫酸卡那霉素注射液，每1000L注射液是由以下原料制成的：氟尼辛葡甲胺30-110kg、硫酸卡那霉素30-110kg、甲氧苄啶50-80kg、依地酸二钠1-20kg、95％乙醇100-400L、冰醋酸1-10L，其余为注射用水。
一种上述的复方硫酸卡那霉素注射液的制备方法，它包括以下步骤：
(1)将甲氧苄啶溶解于冰醋酸中，得到溶液1；
(2)将依地酸二钠放入95％乙醇中，搅拌10-25分钟至澄清得溶液2；
(3)取注射用水300L，依次加入硫酸卡那霉素、氟尼辛葡甲胺搅拌溶解得溶液3；
(4)将上述制得的溶液1，溶液2，溶液3混合，再加注射用水至1000L，搅拌均匀，保持15-20分钟，待药液澄明后即得复方硫酸卡那霉素注射液。
临床试验
实验动物：随机选取患病成猪只180头，体重在40～80kg。
试验药物：本发明实施例1-3制备的复方硫酸卡那霉素注射液；对照1为国标方法制备的硫酸卡那霉素注射液；对照2为国标方法制备的氟尼辛葡甲胺注射液。
试验方法：将180头患猪按体重随机分为六组。其中一组为空白对照组，不给予药治疗；三组为用本发明实施例1-3配方复方硫酸卡那霉素注射液进行治疗，对照1用国标方法制备的硫酸卡那霉素注射液进行治疗；对照2为用国标方法制备的氟尼辛葡甲胺注射液进行治疗。用法：肌肉注射：每1kg体重用0.1～0.15ml，一日1次，连用3天，每试验组用药量相同。治疗开始后，每日记录患蓄身体变化情况和死亡动物分布，治疗10天后统计治疗效果。统计结果如表1所示。
无效：指10天后，患畜症状无明显改变，仍保持治疗前的症状。
有效：指10天后，畜症状有改变，症状优于治疗前的效果。
治愈：指10天后，症状消失，患畜恢复健康。其数字包括在有效数字中。
结束时有症状：指10天后，患畜仍有一定的症状，其症状表现优于治疗前或无改观，患畜没有治愈。其数字已包含在无效头数与有效头数的数字中。
相对增重率：指使用药物后相对于对照组的增重率。
表1临床试验统计结果
从上述表1结果可知，本发明复方硫酸卡那霉素注射液治疗组、硫酸卡那霉素注射液治疗组和氟尼辛葡甲胺注射液治疗组与对照组差异极显著(P＜0.01)。本发明的硫酸卡那霉素注射液疗效比已有两种药物好。
Claims (3)
1.一种复方硫酸卡那霉素注射液，其特征在于：每1000L注射液是由以下原料制成的：氟尼辛葡甲胺30-110kg、硫酸卡那霉素30-110kg、甲氧苄啶50-80kg、依地酸二钠1-20kg、95％乙醇100-400L、冰醋酸1-10L，其余为注射用水。
2.根据权利要求1所述的复方硫酸卡那霉素注射液，其特征在于，每1000L注射液是由以下原料制成的：氟尼辛葡甲胺80kg、硫酸卡那霉素70kg、甲氧苄啶65kg、依地酸二钠10kg、95％乙醇300L、冰醋酸8L，其余为注射用水。
3.一种权利要求1或2所述的复方硫酸卡那霉素注射液的制备方法，其特征在于，它包括以下步骤：
(1)将甲氧苄啶溶解于冰醋酸中，得到溶液1；
(2)将依地酸二钠放入95％乙醇中，搅拌10-25分钟至澄清得溶液2；
(3)取注射用水300L，依次加入硫酸卡那霉素、氟尼辛葡甲胺搅拌溶解得溶液3；
(4)将上述制得的溶液1，溶液2，溶液3混合，再加注射用水至1000L，搅拌均匀，保持15-20分钟，待药液澄明后即得复方硫酸卡那霉素注射液。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710528444.6A CN107281202A (zh) | 2017-07-01 | 2017-07-01 | 一种复方硫酸卡那霉素注射液及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710528444.6A CN107281202A (zh) | 2017-07-01 | 2017-07-01 | 一种复方硫酸卡那霉素注射液及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107281202A true CN107281202A (zh) | 2017-10-24 |
Family
ID=60099763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710528444.6A Pending CN107281202A (zh) | 2017-07-01 | 2017-07-01 | 一种复方硫酸卡那霉素注射液及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107281202A (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103222968A (zh) * | 2012-01-29 | 2013-07-31 | 瑞普（天津）生物药业有限公司 | 一种含有氟尼辛葡甲胺的片剂及其制备方法 |
| CN103222978A (zh) * | 2013-04-02 | 2013-07-31 | 河南省乘风动物保健技术研究所 | 复方磺胺甲噁唑注射液及制备方法 |
-
2017
- 2017-07-01 CN CN201710528444.6A patent/CN107281202A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103222968A (zh) * | 2012-01-29 | 2013-07-31 | 瑞普（天津）生物药业有限公司 | 一种含有氟尼辛葡甲胺的片剂及其制备方法 |
| CN103222978A (zh) * | 2013-04-02 | 2013-07-31 | 河南省乘风动物保健技术研究所 | 复方磺胺甲噁唑注射液及制备方法 |
Non-Patent Citations (2)
| Title |
|---|
| 倪谷音: "兽医常用抗微生物药物的合理使用", 《动保药品》 * |
| 吕惠序: "氨基糖苷类抗生素在猪病防治上的正确使用", 《养猪》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101417018B (zh) | 一种具有清热解毒、凉血止痢功能的兽用注射剂的制备方法 | |
| CN105456321A (zh) | 艾纳香属植物提取物在制备兽药或饲料添加剂中的应用 | |
| CN107281202A (zh) | 一种复方硫酸卡那霉素注射液及其制备方法 | |
| CN101297813B (zh) | 兽用复方烟酸诺氟沙星注射液及其制备方法 | |
| CN101829129B (zh) | 兽用复方硫酸庆大霉素注射液及其制备方法 | |
| CN104824421A (zh) | 一种治疗奶牛隐性牛乳房炎的饲料添加剂 | |
| CN102764252A (zh) | 一种盐酸沃尼妙林的用途 | |
| KR100371090B1 (ko) | 동물용 복합항균제 조성물 | |
| CN101297808B (zh) | 禽用复方氧氟沙星注射液及其制备方法 | |
| CN111493239A (zh) | 一种禽类保健饮用水及其配制方法和应用方法 | |
| CN111494509A (zh) | 一种主治奶牛乳房炎的双丁中药提取注射液及其制备工艺 | |
| KR100371092B1 (ko) | 동물용 복합항균제 조성물 | |
| CN104171498A (zh) | 僵猪脱僵用绿色饲料添加剂及其使用方法 | |
| CN101879179A (zh) | 复方氧氟沙星溶液及其制备方法 | |
| CN104173274A (zh) | 复方盐酸消旋山莨菪碱注射液及制备方法 | |
| CN108653300B (zh) | 一种净化种鸡沙门菌的药物组合物 | |
| CN110693949A (zh) | 一种抗菌消炎兽药组合物及其制备方法 | |
| CN113057985A (zh) | 一种中西药结合的复方盐酸沙拉沙星注射液及其制备方法 | |
| KR100371091B1 (ko) | 동물용 복합항생제 조성물 | |
| CN102319253A (zh) | 用于治疗禽大肠杆菌引起的肠炎的口服液及其制备方法 | |
| CN101422477A (zh) | 复方硫酸安普霉素注射液 | |
| CN101822817A (zh) | 兽用治疗肠道疾病的盐酸多西环素复方注射液及制备方法 | |
| CN101991594A (zh) | 复方盐酸林可霉素注射液及其制备方法 | |
| CN117617390A (zh) | 一种用于仔猪腹泻的复合口服液及其制备方法和应用 | |
| CN114028471A (zh) | 用于预防家禽生殖系统炎症的复方制剂及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171024 |